The Covid-19 pandemic is the nudge the Medicare and Medicaid agency needed to rethink what quality measures it asks providers to report, health policy experts said.
The industry is questioning the utility of having so many quality measures at a moment when doctors and resources are stretched thin. Providers said the measures can be easy to game and arduous to report, and they’re expensive for themselves and the government. Studies have shown some measures may not lead to higher quality care.
The Centers for Medicare & Medicaid Services spent more than $1.3 billion on quality measure development between 2008 and ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.